UK – NICE rejects rare blood cancer treatment Poteligeo in final appraisal

The UK’s National Institute for Health and Care Excellence (NICE) has not recommended Kyowa Kirin’s Poteligeo for the treatment of adults living with rare blood cancers in its final appraisal document (FAD).

Poteligeo (mogamulizumab) is a treatment for adults living with the rare blood cancers mycosis fungoides (MF) and Sézary syndrome (SS), two subtypes of cutaneous T-cell lymphoma (CTCL), who have received at least one prior systemic therapy.

In its FAD, NICE said that clinical trial evidence for Poteligeo is ‘very uncertain’ as the drug was compared with vorinostat, a treatment that is not used or licensed in the UK.

In addition, Poteligeo did not meet NICE’s criteria to be considered a life-extending treatment at the end of life…